# NBPF9

## Overview
Neuroblastoma breakpoint family member 9 (NBPF9) is a gene that encodes the NBPF member 9 protein, which is part of the neuroblastoma breakpoint family. This family of proteins is characterized by their involvement in various cellular processes, although the specific functions of NBPF member 9 remain to be fully understood. The NBPF9 gene has been implicated in several medical conditions, including pituitary stalk interruption syndrome and lung adenocarcinoma, suggesting its potential role in developmental and oncogenic pathways (Wang2020NBPF9; Zhang2015Global). Research indicates that NBPF9 may interact with other proteins, such as LHX3, which is involved in pituitary development, highlighting its possible significance in cellular signaling and regulation (Wang2024Reanalysis). Further studies are needed to elucidate the precise biological functions and mechanisms of NBPF member 9.

## Clinical Significance
Mutations and alterations in the NBPF9 gene have been implicated in several medical conditions. Notably, NBPF9 has been associated with pituitary stalk interruption syndrome (PSIS), a rare congenital defect characterized by anterior pituitary hormone deficiency. In a study involving a young boy with PSIS, a point mutation in NBPF9 (p.L279W) was identified, which was predicted to cause protein structure variation. Functional studies suggested that NBPF9 might interact with LHX3, a protein involved in pituitary development, as knocking down NBPF9 led to a significant decrease in LHX3 protein levels (Wang2024Reanalysis; Wang2020NBPF9).

NBPF9 has also been studied in the context of cancer. It was found to be up-expressed in all four stages of lung adenocarcinoma (ADC), suggesting its potential role as a diagnostic and prognostic biomarker for this type of cancer (Zhang2015Global). The gene's involvement in cancer is further supported by its inclusion in studies analyzing genetic variations and expression changes in various subtypes and stages of lung cancer (Zhang2015Global). Despite these findings, the precise mechanisms by which NBPF9 contributes to these conditions remain to be fully elucidated.


## References


[1. (Wang2024Reanalysis) Shengjie Wang, Qiaozhen Qin, Deyue Jiang, Yan Xiao, Lingtong Ye, Xiaoxia Jiang, and Qinghua Guo. Re-analysis of gene mutations found in pituitary stalk interruption syndrome and a new hypothesis on the etiology. Frontiers in Endocrinology, February 2024. URL: http://dx.doi.org/10.3389/fendo.2024.1338781, doi:10.3389/fendo.2024.1338781. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2024.1338781)

[2. (Wang2020NBPF9) Cheng-Zhi Wang, Ling-Ling Guo, Qing-Hua Guo, and Yi-Ming Mu. Nbpf9 gene may be involved in congenital hypopituitarism: a whole-genome study of a boy with pituitary stalk interruption syndrome and his family. International Journal of Endocrinology, 2020:1–9, July 2020. URL: http://dx.doi.org/10.1155/2020/5401738, doi:10.1155/2020/5401738. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1155/2020/5401738)

[3. (Zhang2015Global) Yong Zhang, Haiyun Wang, Jian Wang, Lianming Bao, Lingyan Wang, Jiayuan Huo, and Xiangdong Wang. Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. Cancer and Metastasis Reviews, 34(2):249–264, May 2015. URL: http://dx.doi.org/10.1007/s10555-015-9558-0, doi:10.1007/s10555-015-9558-0. This article has 103 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10555-015-9558-0)